// App-Quantinova.ai

: Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).

Researchers

Presenter

  • Raphael Brandao Moreira

Principal Investigators

  • Rana R. McKay

  • Wanling Xie

  • Daniel Yick Chin Heng

  • Guillermo de Velasco

  • Daniel E. Castellano

  • Andre Poisl Fay

  • Fabio Augusto Barros Schutz

  • Connor Wells

  • Jo Ann Hsu

  • Sumanta K. Pal

  • Jae-Lyun Lee

  • Robert J. Motzer

  • Darren R. Feldman

  • Toni K. Choueiri

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • PUCRS School of Medicine, Porto Alegre, Brazil

  • City of Hope, Duarte, CA

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber/Harvard Cancer Center, Boston, MA

Locations

  • United States

  • Canada

  • Spain

  • Brazil

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved